NCT05619887

Brief Summary

The goal of this interventional study is to compare muscle reflex function under settings of normoxia (normal oxygen level), acute hypoxia (brief oxygen-lack) and chronic hypoxia (long-duration exposure to oxygen-lack). The main question is: Does the muscle reflex adapt to chronic hypoxia? Young, healthy participants will complete light-to-high intensity cycling exercise with and without suppression of the muscle reflex. Suppression of the muscle reflex will be via spinal administration of the opioid Fentanyl. In the control condition, saline will be administered into the spinal space. Participants will complete control (saline) and experimental (Fentanyl) exercise conditions at sea-level (Kelowna, BC, Canada) breathing room air and whilst breathing a lower fraction of oxygen (acute hypoxia). Thereafter, participants will complete the exercise test after living at high altitude (White Mountain, CA, USA) for 2 weeks whilst breathing room air (chronic hypoxia) and breathing a higher fraction of oxygen (restored normoxia).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 17, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

November 23, 2022

Status Verified

November 1, 2022

Enrollment Period

6 months

First QC Date

November 9, 2022

Last Update Submit

November 19, 2022

Conditions

Keywords

DyspneaExerciseMuscle reflexType III/IV afferents

Outcome Measures

Primary Outcomes (1)

  • Ventilation

    Ventilation, in liters per minute.

    Data collected during steady-state breathing in the last minute of exercise

Secondary Outcomes (1)

  • Mean arterial blood pressure (entire pressure wave)

    Data collected during steady-state breathing in the last minute of exercise

Other Outcomes (1)

  • Exercise performance

    The duration, i.e., however long it takes to complete the exercise; this is typically 7-14 minutes

Study Arms (4)

Sea level control

PLACEBO COMPARATOR

Sea level exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.

Other: Saline

Sea level experimental (muscle reflex suppression)

EXPERIMENTAL

Sea level exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.

Drug: Fentanyl

High altitude control

PLACEBO COMPARATOR

High altitude exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.

Other: Saline

High altitude experimental (muscle reflex suppression)

EXPERIMENTAL

High altitude exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.

Drug: Fentanyl

Interventions

Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.

Also known as: fentaNYL Citrate
High altitude experimental (muscle reflex suppression)Sea level experimental (muscle reflex suppression)
SalineOTHER

An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.

High altitude controlSea level control

Eligibility Criteria

Age19 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • aged 19 - 40 years old
  • not taking medications (exception oral contraception)
  • no history of cardiovascular, respiratory or neurological disease
  • members of the high altitude expedition to White Mountain in 2023

You may not qualify if:

  • post-menopausal or pregnant
  • obese
  • current smokers
  • taking prescription medications that may affect responses to exercise
  • All potential participants will be screened by a physician to identify co-morbidities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of British Columbia - Okanagan Campus

Kelowna, British Columbia, V1V1V7, Canada

Location

Related Publications (2)

  • Amann M, Proctor LT, Sebranek JJ, Pegelow DF, Dempsey JA. Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans. J Physiol. 2009 Jan 15;587(1):271-83. doi: 10.1113/jphysiol.2008.163303. Epub 2008 Nov 17.

  • Wan HY, Weavil JC, Thurston TS, Georgescu VP, Bledsoe AD, Jessop JE, Buys MJ, Richardson RS, Amann M. The muscle reflex and chemoreflex interaction: ventilatory implications for the exercising human. J Appl Physiol (1985). 2020 Oct 1;129(4):691-700. doi: 10.1152/japplphysiol.00449.2020. Epub 2020 Aug 20.

MeSH Terms

Conditions

DyspneaSprains and StrainsMotor Activity

Interventions

FentanylSodium Chloride

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsWounds and InjuriesBehavior

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Philip N Ainslie, PhD

    University of British Columbia- Okanagan

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Travis D Gibbons, PhD

CONTACT

Philip N Ainslie, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
The participant will not know whether they are receiving placebo or fentanyl. The primary investigator will also no know if the participant is receiving placebo or fentanyl.
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Participants will complete all interventions (control and experimental) following drug washout.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 9, 2022

First Posted

November 17, 2022

Study Start

June 1, 2023

Primary Completion

December 1, 2023

Study Completion

June 1, 2024

Last Updated

November 23, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

No personal data will be made available publicly or to other researchers.

Locations